ReviewCureus2026
Decoding the Neurological Connection Between Rosacea and Migraines: Exploring Shared Mechanisms.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosacea and migraine are prevalent chronic disorders traditionally viewed as distinct conditions affecting separate organ systems. However, emerging evidence suggests a significant overlap, notably through shared neurovascular and neuroinflammatory pathways. This literature review explores the mechanisms linking rosacea, a chronic inflammatory skin condition characterized by facial flushing and sensitivity, and migraine, a neurological disorder marked by recurrent headaches. Current research highlights the critical roles of neuropeptides, including calcitonin gene-related peptide (CGRP), substance P (SP), and pituitary adenylate cyclase-activating polypeptide (PACAP), in mediating inflammation and vascular dysregulation common to both conditions. Despite these advances, notable gaps remain, such as limited data on the impact of migraine treatments (e.g., CGRP inhibitors) on rosacea, unclear reasons behind the selective comorbidity of these conditions, minimal research comparing rosacea to other headache disorders, and methodological limitations across studies. Addressing these gaps through interdisciplinary research holds promise for improved clinical outcomes. This review underscores the importance of recognizing rosacea and migraine as interrelated neurovascular disorders, advocating for integrated therapeutic approaches, and proposing directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.